TRANSMITTAL FORM (to be used for all correspondence after initial)		U.S. Patens are required to respond to a collection Application Number Filing Date First Named Inventor Art Unit Examiner Name Attorney Docket Number	PTO/SB/21 (03-03) Approved for use through 04/30/2003. OMB 0651-0031 t and Trademark Office; U.S. DEPARTMENT OF COMMERCE of information unless it displays a valid OMB control number. 10/603,006 06/23/2003 David S. F. Young 1641 (unassigned)
Total Number of Pages in This Submission	· · · · · · · · · · · · · · · · · · ·	LOSURES (Check all that	2056.023
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53		Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Addre Terminal Disclaimer Request for Refund CD, Number of CD(s)	After Allowance Communication to a Technology Center (TC) Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below):
Firm Ferris H. Lander or McHale & Slavin, P.A. Individual Signature	FURE C	OF APPLICANT, ATTORN	EY, OR AGENT

	/ (
CERTIFICATE OF TRANSMISSION/MAILING						
hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United <u>States Postal Service with sufficient postage</u> as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:						
Typed or printed	Debra N. Gerstemeier ()					
Signature	(() Statution	Date	1-29-201W			

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

FEB 0 2 2004 THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT

: David S. F. Young et al

INVENTION

: CANCEROUS DISEASE MODIFYING ANTIBODIES

SERIAL NUMBER

: 10/603,006

FILING DATE

: June 23, 2003

EXAMINER

: (not assigned yet)

GROUP ART UNIT

: 1641

ATTORNEY DOCKET NO.

: 2056.023

CERTIFICATE UNDER 37 CFR §1.8(a)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 1.-297

COCXI

SUPPLEMENTAL PRELIMINARY AMENDMENT

Mail Stop Non-Fee Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

Prior to examination on the merits, please amend the above-referenced application as follows:

Amendments to the Specification begin on page 2 of this paper.

Remarks/Arguments begin on page 3 of this paper.